NCT06116019 Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
| NCT ID | NCT06116019 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Charite University, Berlin, Germany |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 649 participants |
| Start Date | 2023-10-11 |
| Primary Completion | 2026-10-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 649 participants in total. It began in 2023-10-11 with a primary completion date of 2026-10-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (ART) using the Varian/SHS ETHOS treatment system. In this study, radiation treatment plans are dynamically adjusted on a daily basis over several weeks of therapy to account for anatomical shifts in either the tumour or adjacent normal tissue - a capability that has been difficult to achieve due to technical limitations. With the ETHOS accelerator, such real-time adjustments can be made based on cone beam computed tomography (CBCT). This is a prospective observational study with the primary objective of investigating the feasibility and acceptability of performing ART with ETHOS for different tumour entities. The study will also evaluate the feasibility of integrating multi-parametric data sets into the ART workflow, such as standardised electronic feedback on treatment toxicity from both patients (ePROMS) and physicians (ePRT).
Eligibility Criteria
Inclusion Criteria: * Adult patients (\>18 years) * All tumor entities with an indication for radiotherapy and/or chemoradiotherapy * Signed informed consent Exclusion Criteria: * Pregnancy * Patients who are not capable of giving consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06116019 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06116019 currently recruiting?
Yes, NCT06116019 is actively recruiting participants. Contact the research team at goda.kalinauskaite@charite.de for enrollment information.
Where is the NCT06116019 trial being conducted?
This trial is being conducted at Berlin, Germany.
Who is sponsoring the NCT06116019 clinical trial?
NCT06116019 is sponsored by Charite University, Berlin, Germany. The trial plans to enroll 649 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.